IQVIA Holdings Inc. $IQV Stock Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 12.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 282,916 shares of the medical research company’s stock after acquiring an additional 30,348 shares during the quarter. Vontobel Holding Ltd.’s holdings in IQVIA were worth $76,062,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Cyndeo Wealth Partners LLC acquired a new position in IQVIA during the 3rd quarter valued at $315,000. Hanson & Doremus Investment Management increased its holdings in shares of IQVIA by 1.7% during the third quarter. Hanson & Doremus Investment Management now owns 15,699 shares of the medical research company’s stock worth $4,221,000 after buying an additional 257 shares in the last quarter. Pension & Wealth Management Advisors Inc. bought a new position in shares of IQVIA in the third quarter valued at about $30,000. Howard Capital Management LLC bought a new stake in shares of IQVIA during the third quarter worth $242,000. Finally, Goelzer Investment Management Inc. boosted its stake in shares of IQVIA by 2.7% in the 3rd quarter. Goelzer Investment Management Inc. now owns 11,090 shares of the medical research company’s stock valued at $2,982,000 after purchasing an additional 290 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of NYSE IQV traded down $4.04 during mid-day trading on Friday, hitting $267.00. 1,037,035 shares of the stock traded hands, compared to its average volume of 1,546,768. The firm has a 50 day simple moving average of $260.76 and a two-hundred day simple moving average of $212.85. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $277.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market cap of $43.95 billion, a PE ratio of 33.13, a price-to-earnings-growth ratio of 2.35 and a beta of 1.17.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the previous year, the business earned $2.81 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 11.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Mizuho upped their price target on IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Finally, UBS Group started coverage on IQVIA in a report on Wednesday, September 30th. They set a “buy” rating and a $345.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $276.00.

Insider Activity

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.